Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17968325 | 0.79 | EGLN1 (0.31) | EGLN1 | |
| SCHEMBL14468053 | 0.76 | GRIN2D (0.31) | — | |
| SCHEMBL22965656 | 0.76 | AMY1A (0.36) | GRM2EGLN1 | |
| SCHEMBL3392523 | 0.76 | POLB (0.34) | — | |
| SCHEMBL3394106 | 0.76 | RIPK1 (0.43) | GRM2EGLN1 | |
| SCHEMBL30161793 | 0.72 | DYRK1A (0.34) | EGLN1 | |
| SCHEMBL20699401 | 0.72 | DYRK1A (0.34) | EGLN1 | |
| SCHEMBL14445627 | 0.72 | EIF4A3 (0.30) | — | |
| SCHEMBL29285947 | 0.72 | MEN1 (0.42) | — | |
| SCHEMBL30989163 | 0.72 | MEN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021026375-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN | ALKERMES, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026375-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN | ALKERMES, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | GRM2 2245/4885EGLN1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.